
Nanobiotix presents outcomes from trial of JNJ-1900 for pancreatic cancer
Nanobiotix has presented complete outcomes from the dose escalation and dose expansion phases of the Phase I trial of JNJ-1900 (NBTXR3) in treating individuals with locally advanced or borderline resectable pancreatic cancer (LAPC or BRPC). The University …